Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial
Published Online: 2025-02-05
Journal: Nature MedicineLoading...
Authors: Angelo Maiolino•Aurore Perrot•Christopher P. Venner•Cyrille Hulin•Hiroyuki Takamatsu•Jessica Vermeulen•Jianping Wang•Jodi Carey•Josep M. Martí•Katherine Chastain•Kenshi Suzuki•Lorena Lopez-Masi•Ludek Pour•Marc Braunstein•Maria Krevvata•Mehmet Turgut•Melissa Rowe•Meral Beksac•Morio Matsumoto•Nizar J. Bahlis•Robin Carson•Saad Z. Usmani•Sebastian Grosicki•Sonja Zweegman•Supratik Basu•Tahamtan Ahmadi•Thierry Facon•Vania Hungria•Weiping Liu•Wojciech Legiec•Yael C. Cohen
